CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Canagliflozin, a Sodium Glucose co-transporter 2 (SGLT2) inhibitor, improves indices of β-cell function in patients with type 2 diabetes on metformin plus sulphonylurea
DOI 10.1055/s-0033-1341736
Bibliografische Angaben
Nachweis in CareLit
Autor:innenD Polidori, F Vercruysse, E Ferrannini
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Question: Progressive loss of β-cell function (βCF) is thought to underlie the pathophysiology of type 2 diabetes mellitus (T2DM). Canagliflozin (CANA), an inhibitor of SGLT2, is in development for the treatment of T2DM. In hyperglycaemic, partially pancreatectomised rats, βCF can be restored when normoglycaemia is achieved with SGLT2 inhibitor treatment. In a Phase 3 study, 26 weeks of CANA monotherapy treatment im…
Zitieren
Zitierempfehlung
D Polidori, F Vercruysse, E Ferrannini (2013) Canagliflozin, a Sodium Glucose co-transporter 2 (SGLT2) inhibitor, improves indices of β-cell function in patients with type 2 diabetes on metformin plus sulphonylurea. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0033-1341736
Mit CareLit weiterarbeiten